Израиль - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Израиль - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Израиль - иврит - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

Израиль - иврит - Ministry of Health

astrazeneca (israel) ltd - zolmitriptan - טבליות מצופות פילם - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.

Израиль - иврит - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Израиль - иврит - Ministry of Health

eldan electronic instruments co ltd - ioflupane - תמיסה להזרקה - ioflupane 74 mbq/ml - iodine ioflupane (123i) - other dopaminergic agents - datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - of patients with clinically uncertain parkinsonian syndromes in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson's disease multiple system atrophy and progressive supranuclear palsy. - datscan is unable to discriminate between parkinson's disease multiple system atrophy and progressive supranuclear palsy. - to help differentiate probable dementia with lewy bodies from alzheimer's disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson's disease dementia

Израиль - иврит - Ministry of Health

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride

Израиль - иврит - Ministry of Health

rafa laboratories ltd - phenoxybenzamine hydrochloride - קפסולות - phenoxybenzamine hydrochloride 10 mg - phenoxybenzamine - phenoxybenzamine - pheochromocytoma, benign prostatic hypertrophy.

Израиль - иврит - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

Израиль - иврит - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.